Poor
Not Aligned
Patient Risk:
Low
Summary
All extracted claims about lab monitoring for Vascepa are not present in the provided label; the claims are not supported by the prescribing information.
Category Scores
Accurate Statements
Unsupported Statements
The most common lab monitoring is periodic blood work to check overall health parameters and look for medication-related issues.
Not present in label.
The exact schedule depends on your baseline labs and your risk factors.
Not present in label.
Many clinicians check relevant labs at baseline.
Not present in label.
Many clinicians repeat them at regular intervals (often about every 3 to 6 months) while you’re on therapy.
Not present in label.
People most often get labs that align with Vascepa’s monitoring needs and their underlying conditions.
Not present in label.
Liver-related labs (because many patients taking cardiovascular risk medications already have liver monitoring) are included in monitoring.
Not present in label.
A lipid panel is checked to track response in triglycerides and cardiovascular risk management.
Not present in label.
Other routine safety labs your clinician uses for your individual risk profile.
Not present in label.
The prescriber may test more often if you have abnormal baseline liver tests or other existing lab issues.
Not present in label.
The prescriber may test more often if you have significant cardiovascular comorbidities.
Not present in label.
The prescriber may test more often if there are medication changes or dose adjustments.
Not present in label.
The prescriber may test more often if new symptoms that need evaluation (like unusual bleeding/bruising concerns) occur.
Not present in label.
You should check sooner than your usual schedule if you develop symptoms that could suggest a complication.
Not present in label.
You should check sooner if your clinician asks for repeat labs after a change in treatment plan.
Not present in label.
Contradictions
Important Omissions
Label does not provide monitoring guidance or lab-tracking recommendations for Vascepa in the extracted claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Discrepancies pertain to labeling content; no direct patient safety risk from the evaluation itself.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
Claims about monitoring and lab schedules are not supported by the label.
Suggested Improvement
Limit statements to label-supported monitoring guidance; avoid general or implicit monitoring recommendations not found in the official prescribing information.